| Thomas David Lamkin, MD | |
|
3181 Sw Sam Jackson Park Rd, Oregon Health Sciences University, Portland, OR 97239-3011 | |
| (503) 418-1543 | |
| Not Available |
| Full Name | Thomas David Lamkin |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Hematology-oncology |
| Location | 3181 Sw Sam Jackson Park Rd, Portland, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033127576 | NPI | - | NPPES |
| 297505 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0207X | Pediatrics - Pediatric Hematology-oncology | MD24737 (Oregon) | Primary |
| Entity Name | University Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376709535 PECOS PAC ID: 4880760107 Enrollment ID: O20080910000013 |
News Archive
Epocal, Inc., a leading edge provider of point of care technology, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market its new lactate test on the epoc Blood Analysis System. Lactate measurements from the epoc System are used to evaluate acid-base status and for diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).
Today, Pharmanest AB announced that the first patient has been dosed in a randomized Phase II study of SHACT, a product developed for pain relief associated with intrauterine device (IUD) insertion. Karolinska Development AB (STO:KDEV) owns 58.9 percent of Pharmanest.
Researchers at Duke University have discovered a way to enhance the effectiveness and safety of sonogenetics or ultrasonic modulation, emerging techniques that use sound waves to control the behavior of individual neurons or to promote tissue growth and wound healing in other cells.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas David Lamkin, MD 3181 Sw Sam Jackson Park Rd, Oregon Health Sciences University, Portland, OR 97239-3011 Ph: (503) 418-1543 | Thomas David Lamkin, MD 3181 Sw Sam Jackson Park Rd, Oregon Health Sciences University, Portland, OR 97239-3011 Ph: (503) 418-1543 |
News Archive
Epocal, Inc., a leading edge provider of point of care technology, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market its new lactate test on the epoc Blood Analysis System. Lactate measurements from the epoc System are used to evaluate acid-base status and for diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).
Today, Pharmanest AB announced that the first patient has been dosed in a randomized Phase II study of SHACT, a product developed for pain relief associated with intrauterine device (IUD) insertion. Karolinska Development AB (STO:KDEV) owns 58.9 percent of Pharmanest.
Researchers at Duke University have discovered a way to enhance the effectiveness and safety of sonogenetics or ultrasonic modulation, emerging techniques that use sound waves to control the behavior of individual neurons or to promote tissue growth and wound healing in other cells.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.
› Verified 1 days ago
Dr. Sharon Sarah Green Gorini, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3181 Southwest Sam Jackson Park Road, Oregon Health And Science University Mail-dc9r, Portland, OR 97239 Phone: 503-418-5170 | |
Megan Furnari, M.D., M.S. Pediatrics Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Road, Portland, OR 97239 Phone: 503-494-8211 | |
Bruce Alan Boston, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-1926 | |
Dr. Karin Ann Selva, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 501 N Graham St, Suite 375, Portland, OR 97227 Phone: 503-413-1600 | |
Dr. Peter H Chang, DO Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 300 N Graham St Ste 250, Portland, OR 97227 Phone: 503-280-3418 Fax: 503-284-7885 | |
George W Bengtson, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4212 Ne Broadway St, Portland, OR 97213 Phone: 503-249-8787 | |
Dr. Amanda K Blockinger Bailey, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6234 N Greeley Ave, Sellwood Medical Clinic, Portland, OR 97217 Phone: 503-595-9300 |